The aim is to inhibit the immune checkpoint, while either simultaneously suppressing the inflammatory responses (blocking IL-1b or IL-17), or inhibiting tumor cell proliferation with mitogen-activated protein kinase and EGFR inhibitors. This evidence concerns the gene IL17A and neoplasm.